HOME >> BIOLOGY >> NEWS
Genetically modified mice provide information on treatments for cocaine dependence

Drug abuse places a tremendous burden on our nation each year, both in terms of crime, law enforcement demands, lost productivity, added costs of health care delivery, and premature death. Among those drugs that are abused, cocaine is considered one of the most powerful. Yet no effective medications exist to treat cocaine abuse, dependence or withdrawal.

In order to develop these needed medications, a better understanding of cocaine's brain mechanisms is required. Although it is known that cocaine acts on at least three different transporter systems -- the dopamine transporter, the serotonin transporter and the norepinephrine transporter -- it is not clear which combination of transporter systems holds the most potential as targets for developing treatments for cocaine abuse.

Recently, a collaborative research effort led by scientists at the University of North Carolina/Chapel Hill and Duke University used genetically-modified mice to provide information about the mediation of cocaine's rewarding effects. These findings promise to guide the development of potential medications for cocaine abuse. Drs. L.A. Dykstra, L.M. Bohn, R.M. Rodriguiz, W.C. Wetsel, R.R. Gainetdinov and M. G. Caron. University of North Carolina at Chapel Hill, Duke University, and Howard Hughes Medical Institute, presented their results at an American Society for Pharmacology & Experimental Therapeutics session at the Experimental Biology 2003 meeting in San Diego. In these studies, mice were genetically altered so they lacked two of the potential mediators of cocaine's effects. One of those mediators was the dopamine transporter, which is considered to be the primary site of cocaine's rewarding effects. The other mediator was the norepinephrine transporter.

Cocaine's rewarding effects were still apparent in mice that were lacking both the dopamine and the norepinephrine transporter. Indeed, cocaine was just as rewarding in mice lacking these targets as in control mice
'"/>

Contact: Sarah Goodwin
eb3press@bellsouth.net
770-270-0989
Federation of American Societies for Experimental Biology
12-Apr-2003


Page: 1 2

Related biology news :

1. Genetically modified bacterium as remedy for intestinal diseases
2. Genetically-engineered marathon mouse keeps on running
3. Purdue scientists: Genetically modified fish could damage ecology
4. Genetically modified E. coli produce plant product used in foods and cosmetics, Science study says
5. Genetically modified crops not necessarily a threat to the environment
6. Genetically engineered mice offer hope for isolating beta cells and treatment of type 2 diabetes
7. Genetically modified crops in India produced greater yields, reduced pesticide use, new study finds
8. Genetically modified crops may pass helpful traits to weeds, study finds
9. Genetically modified eggplants (aubergines) shown to be 30% more productive
10. Genetically modified crops -- what do scientists say?
11. Genetically engineered tomato plant grows in salty water

Post Your Comments:
(Date:8/19/2015)... HAUPPAUGE, N.Y. , Aug. 19, 2015 /PRNewswire/ ... announced that it has entered into a Definitive ... intellectual property, of iris authentication market leader EyeLock ... transaction, VOXX will have a controlling interest in ... is subject to completion of due diligence.  Expanding ...
(Date:8/12/2015)... , Aug. 12, 2015   MedNet Solutions ... the entire spectrum of clinical research, is proud to ... the company,s comprehensive SaaS-based eClinical technology platform, has led ... the first two quarters of 2015.   Q2 2015 ... largest quarters measured by contract value sold in the ...
(Date:8/11/2015)... , August 11, 2015 Today, ZUK ... Already received as well as expected revenues in 2015 that relate ... FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a prominent smartphone manufacturer in ... ZUK selected FPC1 155 for ...
Breaking Biology News(10 mins):VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5MedNet Solutions Experiences Explosive Corporate Growth 2FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2
(Date:8/26/2015)... ... August 26, 2015 , ... Lee ... in the development and manufacture of highly valued cardiac markers used in early ... extensive expertise with protein chemistry has led to the development and commercialization of ...
(Date:8/26/2015)... GERMANTOWN, Md. , Aug. 26, 2015 ... synthetic biology, announced today the closing of its previously ... in full by the underwriters of their option to ... the public offering price of $41.00 per share.  The ... of shares of common stock sold by Intrexon to ...
(Date:8/26/2015)... , August 26, 2015 After litigating ... Europlasma NV relating to P2i United States ... their dispute in the United States ... the part of either party. As a result of the ... of California dismissed the case without ...
(Date:8/26/2015)... ... 2015 , ... The 2015 Epigenomics & Metabolomics Meeting in Boston ... Asymmetrex to share the first report on progress with its crowdsourcing campaign designed ... tissue stem cells. , With a name like “H2A.Z asymmetry,” the new biomarker would ...
Breaking Biology Technology:Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4P2i Settles United States Litigation 2Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 2Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 3Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 4
Cached News: